Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins

被引:16
作者
Zhang, Wenwen [1 ,2 ]
Yang, Xiaoxiao [1 ]
Chen, Yuanli [1 ,3 ,4 ]
Hu, Wenquan [5 ]
Liu, Lipei [6 ]
Zhang, Xiaomeng [6 ]
Liu, Mengyang [6 ]
Sun, Lei [6 ]
Liu, Ying [6 ]
Yu, Miao [6 ]
Li, Xiaoju [6 ]
Li, Luyuan [4 ]
Zhu, Yan [7 ]
Miao, Qing Robert [5 ]
Han, Jihong [1 ,4 ,6 ]
Duan, Yajun [1 ,4 ,6 ]
机构
[1] Hefei Univ Technol, Coll Biomed Engn, Hefei, Anhui, Peoples R China
[2] Tianjin Cent Hosp Obstet & Gynecol, Res Inst Obstet & Gynecol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Minist Educ, Key Lab Immuno Microenvironm & Dis, Tianjin, Peoples R China
[4] Nankai Univ, Minist Educ, Key Lab Bioact Mat, State Key Lab Med Chem Biol, Tianjin, Peoples R China
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] Nankai Univ, Coll Life Sci, Tianjin, Peoples R China
[7] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2018年 / 1863卷 / 02期
基金
中国国家自然科学基金; 对外科技合作项目(国际科技项目); 中国博士后科学基金;
关键词
Akt; AMPK alpha; ERK1/2; Liver steatosis; NgBR; Statin; NONALCOHOLIC FATTY LIVER; X-RECEPTOR; CHOLESTEROL; ATORVASTATIN; DISEASE; SAFETY; STEATOHEPATITIS; EFFICACY; THERAPY; PROTEIN;
D O I
10.1016/j.bbalip.2017.12.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Deficiency of hepatic Nogo-B receptor (NgBR) expression activates liver X receptor alpha (LXR alpha) in an adenosine monophosphate-activated protein kinase alpha (AMPK alpha)-dependent manner, thereby inducing severe hepatic lipid accumulation and hypertriglyceridemia. Statins have been demonstrated non-cholesterol lowering effects including anti-nonalcoholic fatty liver disease (NAFLD). Herein, we investigated if the anti-NAFLD function of statins depends on activation of NgBR expression. In vivo, atorvastatin protected apoE deficient or NgBR floxed, but not hepatic NgBR deficient mice, against Western diet (WD)-increased triglyceride levels in liver and serum. In vitro, statins reduced lipid accumulation in nonsilencing small hairpin RNA-transfected (shNSi), but not in NgBR small hairpin RNA-transfected (shNgBRi) HepG2 cells. Inhibition of cellular lipid accumulation by atorvastatin is related to activation of AMPK alpha, and inactivation of LXR alpha and lipogenic genes. Statin also inhibited expression of oxysterol producing enzymes. Associated with changes of hepatic lipid levels by WD or atorvastatin, NgBR expression was inversely regulated. At cellular levels, statins increased NgBR mRNA and protein expression, and NgBR protein stability. In contrast to reduced cellular cholesterol levels by statin or beta-cyclodextrin, increased cellular cholesterol levels decreased NgBR expression suggesting cholesterol or its synthesis intermediates inhibit NgBR expression. Indeed, mevalonate, geranylgeraniol or geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate or farnesol, blocked atorvastatin-induced NgBR expression. Furthermore, we determined that induction of hepatic NgBR expression by atorvastatin mainly depended on inactivation of extracellular signal-regulated kinases 1/2 (ERK1/2) and protein kinase B (Akt). Taken together, our study demonstrates that statins inhibit NAFLD mainly through activation of NgBR expression.
引用
收藏
页码:177 / 190
页数:14
相关论文
共 41 条
[1]   A new role for Nogo as a regulator of vascular remodeling [J].
Acevedo, L ;
Yu, J ;
Erdjument-Bromage, H ;
Miao, RQ ;
Kim, JE ;
Fulton, D ;
Tempst, P ;
Strittmatter, SM ;
Sessa, WC .
NATURE MEDICINE, 2004, 10 (04) :382-388
[2]   Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and insigs [J].
Adams, CM ;
Reitz, J ;
De Brabander, JK ;
Feramisco, JD ;
Li, L ;
Brown, MS ;
Goldstein, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (50) :52772-52780
[3]   Lipid-lowering efficacy of atorvastatin [J].
Adams, Stephen P. ;
Tsang, Michael ;
Wright, James M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (03)
[4]   DISCOVERY, BIOCHEMISTRY AND BIOLOGY OF LOVASTATIN [J].
ALBERTS, AW .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (15) :J10-J15
[5]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[6]  
[Anonymous], COCHRANE DATABASE SY
[7]   Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis [J].
Athyros, Vasilios G. ;
Tziomalos, Konstantinos ;
Gossios, Thomas D. ;
Griva, Theodora ;
Anagnostis, Panagiotis ;
Kargiotis, Konstantinos ;
Pagourelias, Efstathios D. ;
Theocharidou, Eleni ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
LANCET, 2010, 376 (9756) :1916-1922
[8]   Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia [J].
BakkerArkema, RG ;
Davidson, MH ;
Goldstein, RJ ;
Davignon, J ;
Isaacsohn, JL ;
Weiss, SR ;
Keilson, LM ;
Brown, WV ;
Miller, VT ;
Shurzinske, LJ ;
Black, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02) :128-133
[9]   Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations [J].
Bjorkhem-Bergman, Linda ;
Nylen, Hanna ;
Eriksson, Mats ;
Parini, Paolo ;
Diczfalusy, Ulf .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 118 (06) :499-502
[10]   Inhibition of ERK1/2 and Activation of LXR Synergistically Reduce Atherosclerotic Lesions in ApoE-Deficient Mice [J].
Chen, Yuanli ;
Duan, Yajun ;
Yang, Xiaoxiao ;
Sun, Lei ;
Liu, Mengyang ;
Wang, Qixue ;
Ma, Xingzhe ;
Zhang, Wenwen ;
Li, Xiaoju ;
Hu, Wenquan ;
Miao, Robert Q. ;
Xiang, Rong ;
Hajjar, David P. ;
Han, Jihong .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (04) :948-959